DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

Syphilis and gonorrhoea diagnoses see significant increase

Syphilis and gonorrhoea diagnoses see significant increase

June 11 2018 Annual reporting of sexually transmitted infection diagnoses has increased 0.3% in...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:11
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:42
  • Syphilis and gonorrhoea diagnoses see significant increase

    Syphilis and gonorrhoea diagnoses see significant increase

    Monday, 11 June 2018 14:16
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

inhalerMarch 23 2016

While inhaled corticosteroids are known to increase the risk of pneumonia in chronic obstructive pulmonary disease, the benefits outweigh the risks, a review has concluded.

Conducted by the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), the review also looked at whether there were any differences in the risk of pneumonia between products. It “did not find conclusive evidence of such difference. Pneumonia remains a common side effect for all of them,” said EMA.

“The Committee’s view is that the benefits of inhaled corticosteroids continue to outweigh their risks.” The committee has recommended that product information is now updated “to adequately reflect the current knowledge.”

EMA has said that the findings mean that there will be no change to the way these medicines should be used for the time being. However, it is calling on doctors and patients to be “vigilant for signs and symptoms of pneumonia in patients with COPD as the clinical features of pneumonia overlap with those of exacerbations of the underlying disease.”

Before the recommendation is adopted as the EMA’s final opinion, the PRAC recommendation will be considered by the Committee for Medicinal Products for Human Use (CHMP). “Further details including advice for patients and healthcare professionals will be published at the time of the CHMP opinion,” said EMA.

In a separate EMA announcement, the PRAC has issued advice for doctors and patients using the cancer medicine Zydelig (idelalisib). In particular, it has recommended that patients should receive antibiotics to prevent Pneumocystusjirovecii pneumonia developing. In addition, patients should also be monitored for infection and have regular blood tests for white blood cell counts.

Zydelig can be used in adults with chronic lymphocytic leukaemia (CLL) or who have follicular lymphoma (FL), a form of non-Hodgkin lymphoma.

Links:

EMA inhaled corticosteroids announcement

EMA Zydelig announcement

Clinical News

July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued.
July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued. The MHRA has launched the consultation with...